Skip to main content

Solventum Corp stock price and financials

  • SOLV · NYSE
  • Medical devices
  • Health Care Technology
  • S&P 500
$89.08+0.30%Close 13 Nov 2026
EV / EBITDA
20.26
Beta · 1 year
0.57
Return · 1 year
+20.7%
52-week range$62.38 — $94.16

Share price close 16 Nov 2026

+1.5%1 monthHigh $90.43Low $81.33
$80$82.5$85$87.5$90$92.5Q3 FY2026 report filed 5 Nov 202623 Oct29 Oct4 Nov10 Nov16 Nov
+20.1%6 monthsHigh $92.44Low $73.56
$70$75$80$85$90$95Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 5 Nov 20264 Jun2 Jul30 Jul26 Aug23 Sep20 Oct16 Nov
+12.6%year to dateHigh $92.44Low $62.49
$60$70$80$90$100Q4 FY2025 report filed 27 Feb 2026Q1 FY2026 report filed 5 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 5 Nov 202611 Feb30 Mar14 May1 Jul17 Aug1 Oct16 Nov
+17.9%1 yearHigh $92.44Low $62.49
$60$70$80$90$100Q4 FY2025 report filed 27 Feb 2026Q1 FY2026 report filed 5 May 2026Q2 FY2026 report filed 5 Aug 2026Q3 FY2026 report filed 5 Nov 2026Jan 26Mar 26Apr 26Jun 26Aug 26Sep 26Nov 26

Quarterly or annual report filed

In one paragraph

Solventum Corp reported revenue of $8.32 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 0.9% from fiscal 2024. Net income was $1.56 billion and diluted earnings per share $8.88.

In its latest reported quarter, the third quarter of fiscal 2026 (the three months to 30 Sep 2026), revenue was $1.95 billion, down 7.0% from a year earlier.

Figures from Solventum Corp's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 5 Nov 2026.

Revenue FY2025
$8.32B+0.9%
Net income
$1.56B+225%
Diluted EPS
$8.88+222%
Gross margin
53.5%−2.2 pts
Free cash flow
−$10.00M−101%
Net debt
$4.37B−41.1%

Fiscal 2025 against fiscal 2024; bars show the last 4 fiscal years; net debt is borrowings and operating lease liabilities less cash and short-term investments at the year end.

Revenue and net income fiscal 2022–2025

  • Revenue
  • Net income
$0$2B$4B$6B$8B$10BRevenue, FY22: $8.13BNet income, FY22: $1.34BFY22Revenue, FY23: $8.2BNet income, FY23: $1.35BFY23Revenue, FY24: $8.25BNet income, FY24: $479MFY24Revenue, FY25: $8.32BNet income, FY25: $1.56BFY25

Latest quarter · Q3 FY2026 to 30 Sep 2026, filed 5 Nov 2026 · Full results →

Revenue
$1.95B−7.0% on a year
Gross margin
54.5%+0.3 pts on a year
Operating income
$68.00M−96.0% on a year
Net income
−$12.00M−101% on a year
Diluted EPS
−$0.07−101% on a year
Free cash flow
$97.00M

Comparable companies All of Health Care →

Solventum Corp beside the other S&P 500 members in Health Care Technology, then the largest in Health Care, by market value.

Solventum Corp and comparable companies
CompanyMarket valueDay1 yearRevenue growthNet marginP/E
SolventumSOLV—+0.3%+20.7%———
Veeva SystemsVEEV$49.02B−0.3%+1.5%+16.5%29.3%48.3
Eli LillyLLY$1.37T+1.1%+41.8%+45.5%31.9%49.6
Johnson & JohnsonJNJ$686.1B+0.8%+47.0%+7.8%16.2%42.6
AbbVieABBV$525.9B+0.2%+26.5%+10.7%15.7%51.1
AmgenAMGN$253.8B−0.3%+38.5%+8.2%24.1%27.0
Gilead SciencesGILD$210.2B+0.1%+36.2%+6.5%−12.5%—

Market value and moves at the latest close. Revenue growth compares the last twelve months with the twelve before; net margin and P/E over the last twelve months; P/E is left blank where earnings are negative.

Margins fiscal 2022–2025

  • Gross
  • Operating
  • Net
0%20%40%60%53.5%26.2%18.7%FY22FY23FY24FY25

Solventum Corp revenue by segment, product and region

Fiscal years, as the company cuts its revenue in its annual reports; the change on a year under each figure. A change is left out from a loss, from a sliver of revenue, or across a change in how the company reports.

By segment

Solventum Corp revenue by segment, by fiscal year
RevenueFY 2023FY 2024FY 2025
MedSurg$4.63B$4.64B+0.1%$4.82B+3.9%
Health Information Systems$1.28B$1.31B+1.6%$1.36B+4.1%
Dental Solutions$1.33B$1.29B−2.6%$1.35B+4.2%
Purification and Filtration Segment$689.0M$709.0M+2.9%$497.0M−29.9%
All Other$262.0M$306.0M+16.8%$302.0M−1.3%
Total revenue$8.20B$8.25B$8.32B

By product

Solventum Corp revenue by product, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025
Cost of product$6.30B$6.30B−0.1%$6.35B+0.8%$6.35B+0.0%
Cost of software and rentals$1.83B$1.90B+3.9%$1.91B+0.3%$1.98B+3.7%
Total revenue$8.13B$8.20B$8.25B$8.32B

By country

Solventum Corp revenue by country, by fiscal year
RevenueFY 2022FY 2023FY 2024FY 2025
United States$4.45B$4.47B+0.5%$4.56B+2.0%$4.67B+2.4%
International$3.68B$3.73B+1.2%$3.69B−0.8%$3.66B−1.0%
Total revenue$8.13B$8.20B$8.25B$8.32B

Financial statements

Fiscal years, the latest ending 31 Dec 2025. Amounts in USD. On a narrow screen the table opens on the latest year and scrolls back.

Income statement

Solventum Corp income statement, annual
PeriodFY 2022FY 2023FY 2024FY 2025
Revenue$8.13B$8.20B$8.25B$8.32B
Revenue growth—+0.8%+0.7%+0.9%
Gross profit$4.70B$4.69B$4.59B$4.45B
Operating income$1.69B$1.69B$1.04B$2.18B
Net income$1.34B$1.35B$479.0M$1.56B
Diluted EPS$7.78$7.79$2.76$8.88
Gross margin57.7%57.3%55.6%53.5%
Operating margin20.8%20.6%12.6%26.2%
Net margin16.5%16.4%5.8%18.7%

Cash flow

Solventum Corp cash flow, annual
PeriodFY 2022FY 2023FY 2024FY 2025
Operating cash flow$1.68B$1.92B$1.19B$369.0M
Capital expenditure$251.0M$290.0M$380.0M$379.0M
Free cash flow$1.43B$1.63B$805.0M−$10.00M

Balance sheet and shares

Solventum Corp balance sheet and shares, annual
PeriodFY 2022FY 2023FY 2024FY 2025
Cash and equivalents$61.00M$194.0M$762.0M$878.0M
Total debt—$98.00M$8.18B$5.25B
Shareholders' equity$11.74B$11.67B$2.96B$5.05B
Diluted shares173M173M174M175M

Quarterly figures

The last eight fiscal quarters, the latest ending 30 Sep 2026. Year-on-year growth compares the same quarter of the previous fiscal year.

Solventum Corp quarterly financial figures
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$2.08B$2.07B$2.16B$2.10B$2.00B$2.01B$2.21B$1.95B
Revenue, year on year+1.9%+2.7%+3.8%+0.7%−3.7%−3.0%+2.2%−7.0%
Gross margin53.9%53.8%54.4%54.2%51.4%54.7%58.2%54.5%
Operating income$136.0M$152.0M$214.0M$1.69B$124.0M$81.00M$181.0M$68.00M
Net income$31.00M$137.0M$90.00M$1.27B$63.00M$13.00M$92.00M−$12.00M
Diluted EPS$0.18$0.78$0.51$7.22$0.36$0.07$0.53−$0.07
Free cash flow$92.00M−$80.00M$59.00M−$21.00M$32.00M−$273.0M$144.0M$97.00M

Operating KPIs

The operating figures Solventum Corp reports beside its statements, then its revenue by product, segment and region, latest period first. Each links to its full history.

Solventum Corp operating KPIs
KPILatestPeriodChange on a yearRecent periods
Organic growth (change on a year)−4.2%quarter to 30 Sep 2026down 7.6 points
Cost of product revenue$1.4Bquarter to 30 Sep 2026down 10.2%
Cost of software and rentals revenue$518.0Mquarter to 30 Sep 2026up 3.2%
Infection Prevention and Surgical Solutions revenue$683.0Mquarter to 30 Sep 2026down 5.4%
Advanced Wound Care revenue$528.0Mquarter to 30 Sep 2026up 8.9%
MedSurg revenue$1.2Bquarter to 30 Sep 2026up 0.4%
Health Information Systems revenue$356.0Mquarter to 30 Sep 2026up 3.2%
Dental Solutions revenue$317.0Mquarter to 30 Sep 2026down 6.8%

Method

Each period is read from the report the company filed and checked against accounting identities before it is shown; a figure that does not pass is left blank rather than estimated. Free cash flow is operating cash flow less capital expenditure. Fiscal years follow the company's own calendar. See data and methodology.

The same figures as plain text and JSON.

Questions

What was Solventum Corp's revenue in fiscal 2025?

$8.32 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), as reported in its annual report.

What was Solventum Corp's net income in fiscal 2025?

$1.56 billion for fiscal year 2025 (the twelve months to 31 Dec 2025).

What were Solventum Corp's diluted earnings per share in fiscal 2025?

$8.88 for fiscal year 2025 (the twelve months to 31 Dec 2025).

What is Solventum Corp's gross margin?

53.5% for fiscal year 2025 (the twelve months to 31 Dec 2025): gross profit divided by revenue.

What is Solventum Corp's operating margin?

26.2% for fiscal year 2025 (the twelve months to 31 Dec 2025): operating income divided by revenue.

How much free cash flow did Solventum Corp generate in fiscal 2025?

−$10.0 million for fiscal year 2025 (the twelve months to 31 Dec 2025): operating cash flow less capital expenditure.

Where does Solventum Corp's revenue come from?

In fiscal 2025, by segment: MedSurg $4.82B (58%), Health Information Systems $1.36B (16%), Dental Solutions $1.35B (16%), Purification and Filtration Segment $497.0M (6.0%), out of $8.32B in all, as stated in its annual report.

In the terminal

Twenty years of Solventum Corp's figures, KPIs, guidance and a cash-flow valuation.

  • Every report line and operating figure, quarter by quarter
  • Guidance against what was delivered
  • Insider trades and institutional holders
  • Alerts on results, filings and price
See plans